Lung toxicity is one of the rare side effects of mitomycin C (MMC), an effective antineoplastic agent. There have been only few reports on pulmonary damage after MMC monotherapy. We describe a case of a pulmonary reaction following MMC monotherapy. The patient was examined including bronchoalveolar lavage (BAL) and transbronchial lung biopsy. BAL yielded the diagnosis of a lymphocyte alveolitis with normal CD4/CD8 ratio within the T lymphocytes. Histologically a florid alveolitis was diagnosed. Radiological and CT findings including HR-CT are described.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Phase III, Double-Blind, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Metformin Hydrochloride and Myo-Inositol Compared to Metformin in Patients With Polycystic Ovary Syndrome.
Cureus
December 2024
Department of Medical Affairs, Eris Lifesciences Ltd., Ahmedabad, IND.
Background Polycystic ovary syndrome (PCOS) poses a significant health concern among reproductive-aged women and is characterized by ovarian dysfunction, hyperandrogenism, and insulin resistance. This study aims to assess the efficacy and safety of metformin and myo-inositol combination therapy compared to metformin monotherapy in patients with PCOS. Materials and methods This was a phase III, double-blind, randomized controlled clinical trial.
View Article and Find Full Text PDFSynergistic effect of repurposed mitomycin C in combination with antibiotics against Aeromonas infection: In vitro and in vivo studies.
J Microbiol Immunol Infect
December 2024
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Aeromonas infections pose a significant threat associated with high mortality rates. This study investigates the potential of mitomycin C (MMC), an anticancer drug, as a novel antimicrobial agent against Aeromonas infections.
Methods: We evaluated the minimum inhibitory concentrations (MICs) of MMC and antibiotics against clinical Aeromonas isolates using broth microdilution.
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
J Immunother Cancer
August 2024
Alpine Immune Sciences Inc, Seattle, Washington, USA.
Article Synopsis
- - Davoceticept (ALPN-202) is an experimental treatment designed to enhance immune response by targeting PD-L1 and CTLA-4, and its effectiveness was assessed in two studies: NEON-1 (monotherapy) and NEON-2 (in combination with pembrolizumab) on patients with advanced solid tumors.
- - In NEON-1, 58 participants received varying doses of davoceticept, and in NEON-2, 29 patients received davoceticept alongside pembrolizumab, with safety and efficacy monitored through adverse events and tumor response.
- - Results indicated that 67% of participants in NEON-1 and 62% in NEON-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Int J Gynecol Cancer
August 2024
Gynecologic Oncology Group (GOG) Foundation, Prague, Czech Republic.
Background: Patients with advanced/recurrent endometrial cancer have a poor prognosis and limited treatment options. Biomarkers such as tumor protein 53 () in endometrial cancer can integrate novel strategies for improved and individualized treatment that could impact patient outcomes. In an exploratory analysis of the phase III ENGOT-EN5/GOG-3055/SIENDO study of selinexor maintenance monotherapy 80 mg in advanced/recurrent endometrial cancer, a pre-specified subgroup of patients with wild type (wt) endometrial cancer showed preliminary activity at long-term follow-up with a generally manageable safety profile (median progression-free survival 27.
View Article and Find Full Text PDFBackground: Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy, combined with pembrolizumab, improved recurrence-free survival and distant metastasis-free survival versus pembrolizumab monotherapy in resected high-risk melanoma.
Methods: We did an open-label, randomised, phase 2b, adjuvant study of mRNA-4157 plus pembrolizumab versus pembrolizumab monotherapy in patients, enrolled from sites in the USA and Australia, with completely resected high-risk cutaneous melanoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!